BioCardia Seeks Accelerated FDA Path for CardiAMP Cell Therapy in Ischemic Heart Failure BioCardia, Inc. (NASDAQ: BCDA) has submitted full CardiAMP Heart Failure clinical data to the U.S. Food and Drug Administration and requested a meeting this qua

#BioCardia (NASDAQ: #BCDA) has filed a meeting request with FDA to review CardiAMP HF data and discuss accelerated approval for ischemic HFrEF. Focus is on high‑risk patients with elevated NT‑proBNP who saw meaningful event and QoL benefits.

prismmarketview.com/biocardia-se...

BioCardia Completes FDA Pre-Submission for Helix Transendocardial Delivery Catheter BioCardia, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapies for cardiovascular and pulmonary diseases, has taken an important regulatory

#BioCardia $BCDA Completes FDA Pre-Submission for Helix Transendocardial Delivery Catheter
prismmarketview.com/biocardia-co...